<DOC>
	<DOCNO>NCT00353860</DOCNO>
	<brief_summary>This study evaluate safety effectiveness stem cell transplantation donor T cell ( type lymphocyte , white blood cell ) remove add back . Certain patient bone marrow malignancy undergo transplantation donate stem cell ( cell produce bone marrow mature different blood component white cell , red cell platelet ) generate new normally function bone marrow . However , T-cells donor may see patient cell foreign mount immune response reject , cause call graft-versus-host-disease ( GVHD ) . Therefore , study , T-cells remove donor cell prevent complication . Nevertheless , disadvantage remove T-cells , since important fight viral infection well remain malignant cell . The attack malignant cell call graft-versus-leukemia effect . Therefore , donor T cell give patient ( add back ) later ( 45 100 day transplant ) provide need immunity less risk cause GVHD . Patients 10 55 year age chronic myelogenous leukemia , acute lymphoblastic leukemia , acute myelogenous leukemia , myelodysplastic syndrome , myeloproliferative disorder , chronic lymphocytic leukemia may eligible study . Prospective participant donor screen medical history physical examination , blood test ( include test match genetic compatibility ) , breathe test , chest sinus X-rays , test heart function . They also undergo bone marrow biopsy aspiration . For procedure , do local anesthetic , tablespoon bone marrow withdrawn needle insert hipbone . Participants may undergo apheresis collect lymphocytes research study . This procedure involve collect blood needle arm , similar donate unit blood . The lymphocyte separate remove cell separator machine , rest blood return needle arm . Before treatment begin , patient central venous catheter ( flexible plastic tube ) place vein . This line remain place stem cell transfusion recovery period draw transfuse blood , give medication , infuse donate cell . Preparation transfusion include irradiation chemotherapy . Patients undergo total body irradiation 8 dos give two 30-minute session day 4 day . Four day transfusion , begin take cyclophosphamide , 9days procedure start fludarabine . These anti-cancer drug kill cancer cell prevent rejection donate cell . While patient receive chemotherapy , donor receives daily injection 6 day G-CSF , drug move stem cell bone marrow blood stream . On day 1 2 chemotherapy complete , stem cell infused patient central line . Patients usually stay hospital 20 30 day transplant recover treatment side effect , may include fever , nausea , diarrhea mouth pain , receive blood transfusion , need . Treatment cyclosporine , drug help prevents rejection donate cell GVHD , start day 44 one day first T-cell add-back . Patients return clinic follow-up various test , treatment examination require , minimum visit least twice week 2 4 month transplant ; 4 , 6 , 9 , 12 month , yearly least 3 year .</brief_summary>
	<brief_title>Stem Cell Transplantation T-Cell Add-Back Treat Bone Marrow Malignances</brief_title>
	<detailed_description>Bone marrow stem cell transplant study carry NHLBI BMT Unit focus approach optimize stem cell lymphocyte dose order improve transplant survival increase graft-vs.-leukemia effect . The aim create transplant condition permit rapid donor immune recovery without cause graft-versus-host disease ( GVHD ) use post-transplant immunosuppression conjunction transplant deplete T cell fix low dose , threshold know associated GVHD . A primary objective protocol therefore test whether low dose T cell choose minimizes risk severity GVHD . We find outcome transplant improve use high stem cell dos , successive protocol achieve progressive improvement transplant-related mortality 35 % first protocol 1993 22 % late study . In last study , series , use Nexell Isolex 300i system obtain high CD34+ dos deplete lymphocyte fix CD3+ T cell dose 5 x 10 ( 4 ) /kg . The use cell separator monoclonal antibody cover IDE 8139 . The study focus role cyclosporine prevent GVHD T cell depletion . We find CSA appear protect GVHD graft failure , high incidence complication occur patient receive CSA . To address result shortcoming previous protocol , continue avoid immunosuppression post-transplant , test two hypothesis : ( 1 ) GVHD incidence severity reduce transfuse T cell dose 2 x 10 ( 4 ) /CD3 cell/kg . ( 2 ) Graft rejection prevent increase immunosuppressive intensity pre-transplant preparative regimen use fludarabine cyclophosphamide reduce dose total body irradiation ( 12 Gy instead 13.6 Gy ) . We use vitro cell separation system namely Isolex 300i monoclonal antibody provide CTEP ( anti CD 6 , anti CD2 , anti CD7 ) . This cover continue IND selection CD34+ CD3+ cell T cell deplete peripheral blood stem cell transplantation .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<criteria>INCLUSION CRITERIA PATIENT : Ages 1055 year inclusive ( less 56 ) . Chronic myelogenous leukemia chronic phase A ) Patients treat STI 571 age 41 ( subject regular DSMB review ) ; B ) Age 1055 chronic phase fail treatment STI571 ; C ) Age 1055 accelerate phase blast transformation . Acute lymphoblastic leukemia , category : Adults ( great 18 year ) first remission highrisk feature ( present leukocyte count great 100,000/cu mm , karyotypes t9 ; 22 , t4 , t19 , t11 , biphenotypic leukemia ) . All second subsequent remission , primary induction failure , partially respond untreated relapse . Acute myelogenous leukemia ( AML ) : AML first remission except AML good risk karyotype : AML M3 ( t15 ; 17 ) , AML M4Eo ( inv 16 ) , AML ( 8 ; 21 ) . All AML second subsequent remission , primary induction failure resistant relapse . Myelodysplastic syndrome , category : refractory anemia transfusion dependence , refractory anemia excess blast , transformation acute leukemia , chronic myelomonocytic leukemia . Myeloproliferative disorder ( myelofibrosis , polycythemia vera , essential thrombocythemia ) transformation acute leukemia . Chronic lymphocytic leukemia refractory fludarabine treatment bulky progressive disease thrombocytopenia ( less equal 100,000/microliters ) anemia ( less equal 10 g/dl ) due recent chemotherapy . No major organ dysfunction preclude transplantation . DLCO great equal 60 % predict . Left ventricular ejection fraction : great equal 40 % predict . ECOG performance status 0 1 . For adult : Ability comprehend investigational nature study provide inform consent . For minor : Written inform consent one parent guardian . Informed oral consent minor : The process explain minor level complexity appropriate age ability comprehend . Negative pregnancy test woman childbearing age . INCLUSION CRITERIA DONORS : HLA 6/6 identical family donor . Weight great equal 18 kg . Age less equal 80 year old . Fit receive GCSF give peripheral blood stem cell ( normal blood count , normotensive , history stroke ) . For adult : Ability comprehend investigational nature study provide inform consent . For minor : Written inform consent one parent guardian inform assent : The process explain minor level complexity appropriate age ability comprehend . EXCLUSION CRITERIA RECIPIENT : Patient pregnant . Age le 10 year 56 year . Patients CML chronic phase 41 year STI 571 treatment choice . ECOG performance status 2 . Severe psychiatric illness . Mental deficiency sufficiently severe make compliance BMT treatment unlikely , make informed consent impossible . Major anticipated illness organ failure incompatible survival BMT . DLCO le 60 % predict . Left ventricular ejection fraction : le 40 % predict . Serum creatinine great 3 mg/dl . Serum bilirubin great 4 mg/dl . Transaminases great 3x upper limit normal . HIV positive . History malignancy except basal cell squamous carcinoma skin , positive PAP smear subsequent negative follow . Individuals disease list inclusion criterion debility age make risk intensive myeloablative therapy unacceptable . This include patient receive busulfan treatment 6 month continuously . These patient consider nonmyeloablative allogeneic transplantation protocol . EXCLUSION CRITERIA DONOR Pregnant lactating . Donor unfit receive GCSF undergo apheresis . ( uncontrolled hypertension , history congestive heart failure , unstable angina , thrombocytopenia ) . HIV positive . Donors positive HBV , HCV HTLV1 may use riskbenefit ratio consider acceptable patient investigator . Weight le 18 kg . Age great 80 year . Severe psychiatric illness . Mental deficiency sufficiently severe make compliance BMT treatment unlikely , make informed consent impossible .</criteria>
	<gender>All</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>November 21, 2016</verification_date>
	<keyword>Leukemia</keyword>
	<keyword>Transplant - Mortality</keyword>
	<keyword>Immunosuppression</keyword>
	<keyword>Radiation</keyword>
	<keyword>Cure</keyword>
	<keyword>Peripheral Blood Stem Cells</keyword>
	<keyword>Graft-Versus Leukemia/Myeloma</keyword>
	<keyword>Graft-Versus-Host Disease</keyword>
	<keyword>Cyclosporine</keyword>
	<keyword>Fludarabine</keyword>
</DOC>